uniQure N.V. filings document regulatory, financial, governance, and capital-structure disclosures for a Nasdaq-listed gene therapy company incorporated in the Netherlands. Form 8-K reports cover operating results, corporate updates, Regulation FD disclosures, and clinical or regulatory communications involving programs such as AMT-130 for Huntington’s disease.
Proxy materials describe shareholder voting matters, board governance, executive compensation, equity awards, and related pay-versus-performance disclosures. The filing record also includes formal disclosure categories for material agreements, financing arrangements, risk-related updates, and capital-structure matters connected to uniQure’s development-stage gene therapy portfolio.
uniQure N.V. director Leonard E. Post reported routine equity compensation and a small tax-related sale. On June 10, he received 7,550 restricted share units, each representing one Ordinary Share, and a grant of 13,980 stock options exercisable at $26.82 per share, both vesting in full on the first anniversary of the grant.
On June 11, 1,993 Ordinary Shares were sold at a weighted average price of $27.06 to cover estimated withholding taxes upon RSU vesting, under automatic sale instructions and not as a discretionary trade. After these transactions, Post directly owns 35,494 Ordinary Shares.
uniQure N.V. director Jack Kaye reported a mix of equity grants and a small share sale. He received 7,550 restricted share units under the company’s 2014 Share Incentive Plan, each representing one Ordinary Share, vesting 100% one year after the grant date.
He was also granted a stock option for 13,980 Ordinary Shares at an exercise price of $26.82, vesting in full on the first anniversary of grant and expiring in 2036. After RSU vesting, 1,993 shares were automatically sold at a weighted average price of $27.06 solely to cover estimated withholding taxes, not as a discretionary trade. Following these transactions, Kaye directly holds 25,996 Ordinary Shares.
uniQure N.V. director Rachelle Suzanne Jacques reported a mix of equity compensation and a small tax-related sale of Ordinary Shares. She sold 1,993 shares at a weighted average price of $27.06 per share to cover estimated withholding taxes when restricted share units vested, under automatic, non-discretionary sale instructions. She also received 7,550 restricted share units and 13,980 stock options with a $26.82 exercise price, both vesting 100% on the first anniversary of the grant date, subject to continued service. Following these transactions, she directly holds 33,903 Ordinary Shares.
uniQure N.V. director Balachandran Madhavan reported routine equity compensation and related tax sales. He was granted 7,550 restricted share units, each representing one Ordinary Share, and 13,980 stock options with a $26.82 exercise price, both vesting 100% on the first anniversary of the grant date subject to continued service. Upon vesting of earlier restricted share units, 1,993 shares were sold at a weighted average price of $27.06, solely to cover estimated withholding taxes under automatic sale instructions, not as a discretionary trade. After these transactions, he directly owns 43,254 Ordinary Shares and holds the new unvested options.
UniQure N.V. submitted a Form 144 notice reporting proposed dispositions of Ordinary Shares tied to equity compensation. The filing lists 7,970 Ordinary Shares from restricted stock unit vesting on 06/11/2026 and 10,000 Ordinary Shares from a stock option exercise and sale pursuant to a 10b5-1 plan on 06/15/2026. The filing indicates the exercise-sale on 06/15/2026 was for cash and that the restricted stock units vesting on 06/11/2026 were issued for services rendered.
UniQure N.V. reports a proposed Rule 144 sale of 7,970 ordinary shares tied to restricted stock unit vesting on 06/11/2026. The filing lists a broker, Citigroup Global Markets, Inc., and shows 7,552 ordinary shares sold on 06/10/2026 for $196,725.35. The filing also includes a disclosed share figure of 63,067,485 shares outstanding as of 06/11/2026.